SAEFVIC Rapid report: a new reporting pathway for COVID-19 vaccine AEFI

Reporting adverse events following immunisation (AEFI) is not mandatory in Victoria, however doing so allows the rapid investigation of any potential vaccine or system problems. This helps to ensure a safe and effective immunisation program and it maintains community confidence in vaccines.

The new SAEFVIC Rapid reporting pathway has been launched for reporting any common or expected side effects following a COVID-19 vaccine. Reporting via this pathway will not result in follow up of clinical symptoms however it will contribute to data collection and assist health authorities to understand the frequency of symptoms occurring. Should the vaccinee experience significant side effects, completing the SAEFVIC Extended report is recommended.

For more information on SAEFVIC, symptoms that should be reported, and instructions on how to report, please visit our immunisation reference page below:

MVEC: Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC)


Updated immunisation reference page: Vaccine confidence

We have recently updated our Vaccine confidence immunisation reference page to include the latest information  and resources available to help address people’s questions and concerns about vaccines.

Our page includes information on how to talk to people who have concerns about vaccines, how to tackle misinformation and how to be a vaccine champion in your workplace or community.

To view this page, please click on the following link:

MVEC: Vaccine confidence

 


New immunisation reference page: Myocarditis and pericarditis following mRNA COVID-19 vaccines

Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune conditions. Globally, an increased number of cases above an expected population rate of myocarditis and pericarditis have been reported in individuals who have received mRNA COVID-19 vaccines (eg. Comirnaty™ and Moderna).

Our new reference page discusses the temporal association of myocarditis and pericarditis with mRNA COVID-19 vaccination, symptoms, investigations, as well as the implications on future COVID-19 vaccination.

To read more follow the link below:

MVEC: Myocarditis and pericarditis following mRNA COVID-19 vaccines

 

 


New immunisation reference page: Moderna COVID-19 vaccine

Following the announcement by the Australian Government that 25 million doses (as well as additional variant specific versions) of Moderna's COVID-19 vaccine, Elasomeran, had been secured for the Australian population, this vaccine was last week granted provisional determination by the TGA.

Our new reference page explores the various clinical trials involving Elasomeran, as well as details the immunogenicity, efficacy and safety data available for this vaccine.

To read more follow the link below:

MVEC: Moderna COVID-19 vaccine


New immunisation reference page: COVID-19 mixed vaccine schedules

With the emergence of variant COVID-19 strains, global vaccine supply issues, and the need to rapidly immunise the population, a number of clinical trials are investigating the option of “mixed schedules”. Mixed schedules have been used previously in other vaccination strategies and involve the administration of different vaccine brands to complete a vaccine course.

Our new reference page explores the clinical trials underway which aim to determine the safety of mixed scheduling, the immunogenicity, as well as the recommendations for intervals between doses.

Due to a lack of available data, mixed vaccine schedules are not currently approved in Australia however are in use in Canada and across Europe.

To read more, follow the link below:

MVEC: COVID-19 mixed vaccine schedules

 


Updated immunisation reference pages: TTS, G6PD and COVID-19 vaccines and allergy

We have recently updated some of our immunisation reference pages to include the latest information and recommendations regarding COVID-19 vaccines. To view these pages please follow the links below:

MVEC: Thrombosis with thrombocytopenia syndrome (TTS)
MVEC: G6PD deficiency and vaccines
MVEC: COVID-19 vaccines and allergy


New immunisation reference page: COVID-19 vaccine delivery: workforce training and application process

Due to the volume of immunisations that need to be administered with the rollout of COVID-19 vaccines, an expansion of the current immunisation workforce is required. Specific training and education is needed in order to ensure that the immunisation workforce is appropriately trained to allow each vaccine to be administered safely and effectively.

Our new reference page, COVID-19 vaccine delivery: workforce training and application process, details the frequently asked questions regarding training requirements for each member of the Victorian COVID-19 immunisation workforce.

To read more, follow the link below:

COVID-19 vaccine delivery: workforce training and application process


Raising Children Network - new COVID-19 vaccination: pregnancy and breastfeeding resource

MVEC have partnered with the Raising Children Network to develop a new resource focused on providing COVID-19 vaccine recommendations for women who are pregnant, breastfeeding or planning pregnancy.

To view this article follow the link below:

COVID-19 vaccination: pregnancy and breastfeeding

Further information on vaccines for pregnant and breastfeeding women can be found via our immunisation reference pages below:

MVEC: Maternal vaccination during pregnancy

MVEC: Breastfeeding and immunisations

 

 


New immunisation reference page: COVID-19 vaccination in children

COVID-19 infections have generally produced more severe disease outcomes in adults and the older population, with children generally experiencing milder symptoms. For this reason, initial COVID-19 vaccine clinical trials and vaccine rollouts focused on the adult population.  However, it is recognised that in order to achieve herd immunity within the community, the vaccination of children needs to be considered.

Our new reference page outlines the importance of conducting paediatric focused COVID-19 vaccine clinical trials and summarises the trials that are currently underway.

To read more follow the link below:

MVEC: COVID-19 vaccination in children

 


Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments

Anaphylaxis following immunisation is extremely rare but can be life-threatening if not managed effectively. There are many conditions with similar presentations to anaphylaxis without being true anaphylaxis (eg. vasovagal, anxiety, vocal cord dysfunction) which can make the diagnosis difficult.

The Department of Health and the VicSIS network have put together Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments. This helpful resource provides a comparison of signs and symproms, as well as highlights the importance of measuring tryptase levels in patients with suspected anaphylaxis.

This guidance can be found in the resources section of the below reference page:

MVEC: COVID-19 vaccines and allergy